Sorafenib, a Multikinase Inhibitor: Results from Clinical Trials in Melanoma Patients
作者： Axel Hauschild , Katharina C. Kähler , Friederike Egberts
DOI: 10.1007/978-1-60327-087-8_47
关键词: Melanoma 、 Sorafenib 、 Multikinase inhibitor 、 Randomized controlled trial 、 Clinical trial 、 Dacarbazine 、 Internal medicine 、 Metastasis 、 Chemotherapy 、 Medicine 、 Oncology
摘要: The prognosis of metastatic melanoma is poor with a median survival 6–9 months. Remission rates after systemic treatment range from 5 to 20%, but there no clear effect on overall survival. single-agent chemotherapy dacarbazine (DTIC) often used as reference agent in prospective randomized clinical trials, although striking has never been shown. Thus, an ongoing debate about the appropriate medical for patients advanced (AJCC stage IV).
springer.com
sci-hub.st 参考文章(21)
Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655
A. Pavlick, L. Liebes, I. Osman, P. Brooks, H. Yee, D. Polsky, M. Buckley, A. Hamilton, J. Wright, F. Muggia, Sorafenib down-regulation of the RAS/BRAF/MEK/MAPK pathway: clinical, pathologic and PET correlation Melanoma Research. ,vol. 16, ,(2006) , 10.1097/00008390-200609001-00177
T Eisen, T Ahmad, K T Flaherty, M Gore, S Kaye, R Marais, I Gibbens, S Hackett, M James, L M Schuchter, K L Nathanson, C Xia, R Simantov, B Schwartz, M Poulin-Costello, P J O'Dwyer, M J Ratain, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis British Journal of Cancer. ,vol. 95, pp. 581- 586 ,(2006) , 10.1038/SJ.BJC.6603291
Christopher W. Ryan, Bryan H. Goldman, Primo N. Lara, Philip C. Mack, Tomasz M. Beer, Catherine M. Tangen, Dianne Lemmon, Chong-Xian Pan, Harry A. Drabkin, E. David Crawford, Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group Journal of Clinical Oncology. ,vol. 25, pp. 3296- 3301 ,(2007) , 10.1200/JCO.2007.11.1047
Lena Kanter, Johan Hansson, Anton Platz, Ulrik Ringborg, Katarina Omholt, NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clinical Cancer Research. ,vol. 9, pp. 6483- 6488 ,(2003)
Kapaettu Satyamoorthy, Meenhard Herlyn, Patricia van Belle, Barbara L. Weber, David E. Elder, Patricia Volpe, Marcia S. Brose, Gang Li, Michelle R. Gerrero, Constitutive Mitogen-activated Protein Kinase Activation in Melanoma Is Mediated by Both BRAF Mutations and Autocrine Growth Factor Stimulation Cancer Research. ,vol. 63, pp. 756- 759 ,(2003)
Thomas K Eigentler, Ulrich M Caroli, Peter Radny, Claus Garbe, Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials The Lancet Oncology. ,vol. 4, pp. 748- 759 ,(2003) , 10.1016/S1470-2045(03)01280-4
Charles M. Balch, Antonio C. Buzaid, Seng-Jaw Soong, Michael B. Atkins, Natale Cascinelli, Daniel G. Coit, Irvin D. Fleming, Jeffrey E. Gershenwald, Alan Houghton, John M. Kirkwood, Kelly M. McMasters, Martin F. Mihm, Donald L. Morton, Douglas S. Reintgen, Merrick I. Ross, Arthur Sober, John A. Thompson, John F. Thompson, Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma Journal of Clinical Oncology. ,vol. 19, pp. 3635- 3648 ,(2001) , 10.1200/JCO.2001.19.16.3635
Eric C. McGary, Dina Chelouche Lev, Maribelis Ruiz, Janet E. Price, Lisa Mills, Menashe Bar-Eli, Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Molecular Cancer Therapeutics. ,vol. 2, pp. 753- 763 ,(2003)
Sandra Pavey, Peter Johansson, Leisl Packer, Jennifer Taylor, Mitchell Stark, Pamela M Pollock, Graeme J Walker, Glen M Boyle, Ursula Harper, Sarah-Jane Cozzi, Katherine Hansen, Laura Yudt, Chris Schmidt, Peter Hersey, Kay AO Ellem, Michael GE O'Rourke, Peter G Parsons, Paul Meltzer, Markus Ringnér, Nicholas K Hayward, Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene. ,vol. 23, pp. 4060- 4067 ,(2004) , 10.1038/SJ.ONC.1207563